IP Verse

Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)

Patent No. EP4252857 (titled "Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)") was filed by Regeneron Pharmaceuticals on Sep 12, 2012. The application was issued on Sep 25, 2024.

Patent Summary

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_CFI_195/2025Feb 28, 2025Regeneron Pharmaceuticals, Sanofi BiotechnologyInfringement

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
AMGENJun 23, 2025BIJVANK

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4252857

REGENERON PHARMACEUTICALS
Application Number
EP23176223A
Filing Date
Sep 12, 2012
Status
Granted And Under Opposition
Aug 22, 2024
Publication Date
Sep 25, 2024
External Links
Slate, Register , Google Patents